Drug Discovery World

MARCH 19, 2024

The company plans to submit an Investigational New Drug (IND) application to the FDA for AT-108 by 2026, expand and reinforce its research and development team, and fuel new reprogramming modalities and delivery platforms to strengthen the pipeline.

Immune Response 130

Immune Response Packaging Therapies FDA 130

Drug Discovery World

APRIL 18, 2023

billion by 2026, these drugs are primarily indicated for the treatment of multiple myeloma. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. While the global proteasome inhibitors market is expected to reach nearly $2.3

Therapies 242

Therapies Clinical Development Treatment Marketing 242

Drug Discovery World

MAY 16, 2024

Greenheys at Manchester Science Park is scheduled for completion in Summer 2026 and will span 131,000 sq ft across six floors. Work has started on a £60 ($75.1) million development in Manchester intended to enhance the city’s Oxford Road Corridor knowledge quarter as a hub for life sciences and technology innovation.

Laboratories 147

Laboratories Science Clinical Trials Research 147

Agency IQ

MARCH 25, 2024

BY SCOTT STEPHENS, MPA This week, ECHA finalized its annual update to the Community Rolling Action Plan (CoRAP), listing 28 substances that will be assessed under the REACH Regulation’s substance evaluation procedure during the 2024-2026 period.

59

59

Agency IQ

MARCH 25, 2024

ECHA flags 28 substances for evaluation over next three years This week, ECHA finalized its annual update to the Community Rolling Action Plan (CoRAP), listing 28 substances that will be assessed under the REACH Regulation’s substance evaluation procedure during the 2024-2026 period.

Compliance 40

Compliance Production Regulations 40

Drug Discovery World

APRIL 16, 2024

The first results are expected by early 2026. The study will also evaluate the effect of NX210c on functional outcomes and select secondary biomarkers. Axoltis aims to enrol a total of 80 ALS patients in a trial planned in France with at least 15 investigating sites.

Clinical Trials 130

Clinical Trials Trials Pharmacokinetics Drugs 130

Drug Discovery World

NOVEMBER 23, 2023

Centres in the US are already enrolling patients and results are anticipated by early 2026. “The X-ALD patient community is very excited to have a study commencing in adult cALD where few options are currently available,” said Kathleen O’Sullivan-Fortin, Co-Founder, ALD Connect.

Trials 130

Trials Clinical Trials FDA Approval FDA 130

Drug Discovery World

JULY 14, 2022

Cytiva is planning to start construction on the site in Q3 of 2022 with manufacturing expected to begin in 2026. . Official comments .

Science 130

Science Vaccine Pharmaceuticals Research 130

Drug Discovery World

AUGUST 21, 2023

However, these trials won’t be complete until 2026 at the earliest. It is believed the drug could affect an overall improvement of nerve cells, inflammation and vascular health that could potentially help to slow the clinical progression of Alzheimer’s disease. appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Trials Treatment Licensing 130

Perficient: Drug Development

MAY 30, 2024

.” – Marybeth Wrabel How We’re Approaching Transformation, Modernization, and Mandates There’s plenty of discussion and investment happening already among insurers, as they address interoperability and prepare for a Prior Authorization mandate in 2026.

Regulations 88

Regulations Science Marketing 88

FDA Law Blog: Biosimilars

JUNE 26, 2023

September 1, 2023 will be the selection date for the 10 drugs that will be subject to “maximum fair price” ceilings under Medicare Part D starting in 2026. Chamber of Commerce makes all the arguments that the other plaintiffs have made, and also alleges that Congress has no power to levy the excise tax because it “compels” commerce.

Pharmaceuticals 59

Pharmaceuticals Drugs Research Government 59

The Pharma Data

SEPTEMBER 27, 2021

7.125% Notes due 2025 532457 AM0 3 0.750% due August 31, 2026 0.820% 15 bps $1,222.65 5.500% Notes due 2027 532457 AZ1 7 0.750% due August 31, 2026 0.820% 40 bps $1,226.23 3.100% Notes due 2027 532457 BP2 13 0.750% due August 31, 2026 0.820% 35 bps $1,100.66

Disease 52

Disease Marketing 52

Perficient: Drug Development

DECEMBER 27, 2023

The effective date of the new rule is April 1, 2024, with key provisions taking effect on January 1, 2026, and January 1, 2027. Banks Additionally, the recent rule by the OCC, the Federal Reserve, and the FDIC strengthens and modernizes Community Reinvestment Act (CRA) regulations.

Compliance 52

Compliance Regulations Production 52

Perficient: Drug Development

AUGUST 22, 2023

According to Gartner’s 2022 Industry Cloud Survey , about 40% of IT leaders say they have started to adopt industry cloud platforms, with another 15% in pilots; another 15% are considering deployment by 2026. One of the ways healthcare and life sciences organizations are moving to the cloud is by adopting digital health platforms (DHP).

Science 98

Science Marketing Production 98

The Pharma Data

MARCH 31, 2023

This would support extension of the regulatory data protection to November 2026. If approved, Entresto will become available to children with a new age-appropriate formulation to enable accurate and convenient administration for these patients and their caregivers.

Hospitals 75

Hospitals Trials Treatment Clinical Trials 75

FDA Law Blog: Biosimilars

OCTOBER 12, 2023

Priority is given to Suitability Petitions that could mitigate or resolve a drug shortage; address a public health emergency declared by HHS; mitigate waste by way of new strengths for parenteral products; or subject to special review under the President’s Emergency Plan for Aids Relief.

FDA 59

FDA Drugs Production 59

Drug Discovery World

FEBRUARY 2, 2024

He says: “Then, maybe in 2025/2026, we’re ready to apply vast and dramatic AI models, because then we’ll have it.” He continues to say that the next two or three years will be all about getting what the industry collective knows into a form where we can actually learn from it.

Compliance 130

Compliance Science Pharma Companies Engineering 130

LifeSciVC

APRIL 2, 2024

We have milestones on the horizon, and we want investors to stay close to the Sionna story even if we don’t need capital until 2026. As an example of the continued engagement, we headed to the TD Cowen healthcare conference in early March before the ink was dry on the Series C closing.

Science 68

Science Small Molecule International Clinical Development 68

The Pharma Data

OCTOBER 31, 2020

billion USD by 2026 at a CAGR of 11.5%. With the IND approval in place, we are ready and eager to extend the clinical study of TG-1000 to the U.S. in the near future.” ” According to Global Data, the global market for influenza antivirals reached 2.34 billion USD in 2019 and is estimated to reach 5.03

FDA Approval 52

FDA Approval FDA Virus Clinical Development 52

Drug Discovery World

JANUARY 25, 2023

billion, by 2026 1. The logistics of DCTs The number of clinical trials being conducted via the DCT and hybrid model has increased significantly in recent years, and the pace of change shows no sign of slowing. The market, worth an estimated $8.8 billion in 2021 is expected to increase by 10% year on year, to $14.2

Trials 130

Trials Clinical Trials Laboratories Nurses 130

The Pharma Data

SEPTEMBER 7, 2021

0.750% due August 31, 2026. 0.750% due August 31, 2026. 0.750% due August 31, 2026. 0.750% due August 31, 2026. 3.950% Notes due 2049. 532457 BT4. 1,500,000,000. 2.375% due May 15, 2051. 7.125% Notes due 2025. 532457 AM0. 229,692,000. 6.770% Notes due 2036. 532457 AP3. 174,445,000. 1.250% due August 15, 2031. 532457 BC1.

Licensing 52

Licensing Licensing Marketing 52

The Pharma Data

MAY 2, 2023

Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. This step is crucial for Boehringer Ingelheim to rapidly advance new drug candidates from the company’s vast research pipeline to clinical trials and ultimately to market approval.

Small Molecule 40

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

JUNE 28, 2023

3 The Company is on track to reduce greenhouse gas emissions (GHGs) from its operations and fleet by 98% by 2026 * and halve its entire value chain footprint by 2030, on the way to a 90% absolute emissions reduction and becoming science-based net zero by 2045 ** at the latest.

Science 40

Science Government 40

Agency IQ

MAY 28, 2024

Transitional conditions are given in Article 25 , which set January 12, 2026 as the deadline for member states to ensure compliance with the parametric values for bisphenol A, chlorate, chlorite, haloacetic acids, microcystin-LR, uranium, and total and sum values of per- and polyfluoroalkyl substances (PFAS).

Compliance 40

Compliance Production Pharmaceuticals Treatment 40

The Pharma Data

MARCH 31, 2022

million patients, provided with essential medicines by the global health unit, for the treatment of non-communicable diseases in 40 of the world’s poorest countries, between 2022 and 2026. The coupon amounts are linked to the achievement of a sustainability performance target defined as the cumulative number of patients, being at least 1.5

Government 52

Government Treatment Vaccine Disease 52

Drug Target Review

JANUARY 4, 2024

Then it’s on to dosing and administration studies in animals, pivotal toxicology studies, and, following a successful funding round, first-in-human studies in 2026. We’ve made great progress to date and have every faith that the program will continue to progress with remarkable promise.

Therapies 98

Therapies Small Molecule Production Disease 98

The Pharma Data

DECEMBER 8, 2020

Ionis projects having the opportunity to launch six or more new products through 2026, with each being ready for launch in a close window, ranging from 18 to 24 months between each new product launch. The expectation is that the implementation of this strategy will drive double-digit revenue growth and substantial earnings growth. .

RNA 52

RNA Pharmaceuticals Production Disease 52

FDA Law Blog: Biosimilars

OCTOBER 4, 2023

Note that Astellas withdrew its lawsuit after none of its drugs were selected for price reduction in 2026—potentially because that fact cut against its argument for standing. Harm The Court reviewed the parties’ arguments on “irreparable harm to Plaintiffs.”

Pharmaceuticals 59

Pharmaceuticals Government Regulations Drugs 59

The Pharma Data

APRIL 14, 2021

The five-year project will see the site fully operational in Q1 2026 once all qualifications and validations of the first manufactured vaccine have been completed. The project is currently entering its design phase with construction expected to begin in Q3 2021.

Vaccine 52

Vaccine Production Disease International 52

Agency IQ

MARCH 29, 2024

UCMR5 targets 29 different PFAS and lithium for testing between 2022 and 2026. UCMRs are released every 5 years, with the most recent UCMR, UCMR 5 , released on December 27, 2021.

Regulations 40

Regulations Compliance Production Treatment 40

The Pharma Data

MAY 15, 2023

Work is set to begin this year, with full operations provisionally planned for late 2026. In addition, Sandoz recently signed a Memorandum of Understanding to build a new biologics production plant in Slovenia – an expected investment of at least USD 400 million to support increasing global demand for biosimilar medicines.

Biosimilars 40

Biosimilars Production Government Clinical Trials 40

National Institute on Drug Abuse: Nora's Blog

DECEMBER 14, 2022

Greater involvement of people with lived experience in all aspects of research is one of the themes of NIDA’s 2022-2026 Strategic Plan. All projects will have a community advisory board and/or people with lived experience will have paid positions to support the research.

Research 52

Research Treatment Disease Drugs 52

Drug Target Review

JULY 4, 2023

The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 1 Regulators invest significant consideration balancing quality-of-life measures with overall survival when assessing novel oncology treatments.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

The Pharma Data

JUNE 26, 2021

Those taking up this offer will be required to hold the Shares or the corresponding FCPE units for a period of approximately five years, i.e. until 31 May 2026, except upon the occurrence of an early release event provided for under Article R. The voting rights attached to the subscribed Shares will be exercised directly by the employees.

Regulations 52

Regulations Marketing 52

National Institute on Drug Abuse: Nora's Blog

SEPTEMBER 27, 2022

One of the cross-cutting themes of NIDA’s new FY 2022-2026 Strategic Plan is greater involvement of people with lived experience in research design, and the science of recovery supports is emblematic of how successful that mindset can be.

Research 52

Research Treatment Science Trials 52

The Pharma Data

APRIL 15, 2022

New GSK reaffirms its full-year 2022 guidance, the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**, and long-term sales ambition.

FDA Approval 52

FDA Approval Treatment Trials Clinical Trials 52

Drug Discovery World

OCTOBER 4, 2022

The global lab automation market for drug discovery is expected to grow by a CAGR of 5% between 2021 – 2026, according to a report by Mordor Intelligence. . Automated systems have become a prominent feature throughout drug discovery, helping scientists save time and assisting in reproducible experiments for more verifiable results.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130